-
1
-
-
79952232216
-
Global cancer statistics
-
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
-
(2011)
CA Cancer J Clin
, vol.61
, pp. 69-90
-
-
Jemal, A.1
Bray, F.2
Center, M.M.3
Ferlay, J.4
Ward, E.5
Forman, D.6
-
2
-
-
84878046514
-
Survival of patients with non-small cell lung cancer without treatment: A systematic review and meta-Analysis
-
Wao H, Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B. Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-Analysis. Syst Rev 2013;2:10.
-
(2013)
Syst Rev
, vol.2
, pp. 10
-
-
Wao, H.1
Mhaskar, R.2
Kumar, A.3
Miladinovic, B.4
Djulbegovic, B.5
-
3
-
-
15744362912
-
The 2004 world health organization classification of lung tumors
-
Beasley MB, Brambilla E, Travis WD. The 2004 World Health Organization classification of lung tumors. Semin Roentgenol 2005;40:90-97.
-
Semin Roentgenol
, vol.2005
, Issue.40
, pp. 90-97
-
-
Beasley, M.B.1
Brambilla, E.2
Travis, W.D.3
-
4
-
-
84879071011
-
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
-
Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-2394.
-
(2013)
N Engl J Med
, vol.368
, pp. 2385-2394
-
-
Shaw, A.T.1
Kim, D.W.2
Nakagawa, K.3
-
5
-
-
84857502654
-
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre open-label randomised phase 3 trial
-
Spanish Lung Cancer Group in Collaboration with Groupe Franais de Pneumo-Cancrologie and Associazione Italiana Oncologia Toracica
-
Rosell R, Carcereny E, Gervais R, et al; Spanish Lung Cancer Group in Collaboration with Groupe Franais de Pneumo-Cancrologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-246.
-
(2012)
Lancet Oncol
, vol.13
, pp. 239-246
-
-
Rosell, R.1
Carcereny, E.2
Gervais, R.3
-
6
-
-
0037816165
-
Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis
-
Kato S, Han SY, Liu W, et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A 2003;100:8424-8429.
-
(2003)
Proc Natl Acad Sci U S A
, vol.100
, pp. 8424-8429
-
-
Kato, S.1
Han, S.Y.2
Liu, W.3
-
7
-
-
0030905284
-
Mdm2 promotes the rapid degradation of p53
-
Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-299.
-
(1997)
Nature
, vol.387
, pp. 296-299
-
-
Haupt, Y.1
Maya, R.2
Kazaz, A.3
Oren, M.4
-
8
-
-
0031583962
-
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
-
Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997;420:25-27.
-
(1997)
FEBS Lett
, vol.420
, pp. 25-27
-
-
Honda, R.1
Tanaka, H.2
Yasuda, H.3
-
9
-
-
84905029258
-
Comprehensive molecular profiling of lung adenocarcinoma
-
Cancer Genome Atlas Research Network
-
Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511:543-450.
-
(2014)
Nature
, vol.511
, pp. 543-550
-
-
-
10
-
-
84866894408
-
Comprehensive genomic characterization of squamous cell lung cancers
-
Cancer Genome Atlas Research Network
-
Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489:519-525.
-
(2012)
Nature
, vol.489
, pp. 519-525
-
-
-
11
-
-
0029806936
-
Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53
-
Denissenko MF, Pao A, Tang M, Pfeifer GP. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 1996;274:430-432.
-
(1996)
Science
, vol.274
, pp. 430-432
-
-
Denissenko, M.F.1
Pao, A.2
Tang, M.3
Pfeifer, G.P.4
-
12
-
-
77955363995
-
TP53 mutations in human cancers: Origins, consequences, and clinical use
-
Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2010;2:a001008.
-
(2011)
Cold Spring Harb Perspect Biol
, vol.2
, pp. a001008
-
-
Olivier, M.1
Hollstein, M.2
Hainaut, P.3
-
15
-
-
84876914265
-
MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models
-
Tovar C, Graves B, Packman K, et al. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. Cancer Res 2013;73:2587-2597.
-
(2013)
Cancer Res
, vol.73
, pp. 2587-2597
-
-
Tovar, C.1
Graves, B.2
Packman, K.3
-
16
-
-
84868203735
-
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-Amplified, welldifferentiated or dedifferentiated liposarcoma: An exploratory proof-ofmechanism study
-
Ray-Coquard I, Blay JY, Italiano A, et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-Amplified, welldifferentiated or dedifferentiated liposarcoma: an exploratory proof-ofmechanism study. Lancet Oncol 2012;13:1133-1140.
-
(2012)
Lancet Oncol
, vol.13
, pp. 1133-1140
-
-
Ray-Coquard, I.1
Blay, J.Y.2
Italiano, A.3
-
17
-
-
84880896065
-
Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development
-
Ding Q, Zhang Z, Liu JJ, et al. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J Med Chem 2013;56:5979-5983.
-
(2013)
J Med Chem
, vol.56
, pp. 5979-5983
-
-
Ding, Q.1
Zhang, Z.2
Liu, J.J.3
-
18
-
-
0141566685
-
Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models
-
Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003;9:4227-4239.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 4227-4239
-
-
Voskoglou-Nomikos, T.1
Pater, J.L.2
Seymour, L.3
-
19
-
-
65949099336
-
A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro
-
Daniel VC, Marchionni L, Hierman JS, et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res 2009;69:3364-3373.
-
(2009)
Cancer Res
, vol.69
, pp. 3364-3373
-
-
Daniel, V.C.1
Marchionni, L.2
Hierman, J.S.3
-
21
-
-
78751471036
-
The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in earlystage non-small cell lung cancer
-
John T, Kohler D, Pintilie M, et al. The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in earlystage non-small cell lung cancer. Clin Cancer Res 2011;17:134-141.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 134-141
-
-
John, T.1
Kohler, D.2
Pintilie, M.3
-
22
-
-
84899475102
-
Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts
-
Topp MD, Hartley L, Cook M, et al. Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. Mol Oncol 2014;8:656-668.
-
(2014)
Mol Oncol
, vol.8
, pp. 656-668
-
-
Topp, M.D.1
Hartley, L.2
Cook, M.3
-
23
-
-
84886598463
-
Prognostic value of fibroblast growth factor receptor 1 gene locus amplification in resected lung squamous cell carcinoma
-
Craddock KJ, Ludkovski O, Sykes J, Shepherd FA, Tsao MS. Prognostic value of fibroblast growth factor receptor 1 gene locus amplification in resected lung squamous cell carcinoma. J Thorac Oncol 2013;8:1371-1377.
-
(2013)
J Thorac Oncol
, vol.8
, pp. 1371-1377
-
-
Craddock, K.J.1
Ludkovski, O.2
Sykes, J.3
Shepherd, F.A.4
Tsao, M.S.5
-
24
-
-
78649680251
-
Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer
-
Zhu CQ, Ding K, Strumpf D, et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol 2010;28:4417-4424.
-
(2011)
J Clin Oncol
, vol.28
, pp. 4417-4424
-
-
Zhu, C.Q.1
Ding, K.2
Strumpf, D.3
-
25
-
-
34248379012
-
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database
-
Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007;28:622-629.
-
(2007)
Hum Mutat
, vol.28
, pp. 622-629
-
-
Petitjean, A.1
Mathe, E.2
Kato, S.3
-
26
-
-
33846935466
-
Cancer biology: Gone but not forgotten
-
Sharpless NE, DePinho RA. Cancer biology: gone but not forgotten. Nature 2007;445:606-607.
-
(2007)
Nature
, vol.445
, pp. 606-607
-
-
Sharpless, N.E.1
DePinho, R.A.2
-
27
-
-
84874948475
-
A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis
-
Kracikova M, Akiri G, George A, Sachidanandam R, Aaronson SA. A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis. Cell Death Differ 2013;20:576-588.
-
(2013)
Cell Death Differ
, vol.20
, pp. 576-588
-
-
Kracikova, M.1
Akiri, G.2
George, A.3
Sachidanandam, R.4
Aaronson, S.A.5
-
28
-
-
84871939847
-
Sequence dependence of MEK inhibitor AZD6244 combined with gemcitabine for the treatment of biliary cancer
-
Xu J, Knox JJ, Ibrahimov E, et al. Sequence dependence of MEK inhibitor AZD6244 combined with gemcitabine for the treatment of biliary cancer. Clin Cancer Res 2013;19:118-127.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 118-127
-
-
Xu, J.1
Knox, J.J.2
Ibrahimov, E.3
-
29
-
-
32444449180
-
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy
-
Tovar C, Rosinski J, Filipovic Z, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A 2006;103:1888-1893.
-
(2006)
Proc Natl Acad Sci U S A
, vol.103
, pp. 1888-1893
-
-
Tovar, C.1
Rosinski, J.2
Filipovic, Z.3
-
30
-
-
26444560960
-
Caspases: Pharmacological manipulation of cell death
-
Lavrik IN, Golks A, Krammer PH. Caspases: pharmacological manipulation of cell death. J Clin Invest 2005;115:2665-2672.
-
(2005)
J Clin Invest
, vol.115
, pp. 2665-2672
-
-
Lavrik, I.N.1
Golks, A.2
Krammer, P.H.3
-
31
-
-
84868209130
-
A phase i study of MDM2 antagonist RG7112 in patients (pts) with relapsed/refractory solid tumors
-
abstr e13600
-
Kurzrock R, Blay J-Y, Nguyen BB, et al. A phase I study of MDM2 antagonist RG7112 in patients (pts) with relapsed/refractory solid tumors. Proc Am Soc Clin Oncol 2012;30 (Suppl):abstr e13600.
-
(2012)
Proc Am Soc Clin Oncol
, vol.30
-
-
Kurzrock, R.1
Blay, J.-Y.2
Nguyen, B.B.3
|